[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Draig Therapeutics Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100639900","phase-2-a-study-to-evaluate-the-effectiveness-of-dt-101-as-an-adjunctive-treatment-in-patients-with-depression-100639900",false,"NCT07610473","A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression","A Phase 2 Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder Receiving Pharmacological Therapy for Depression","AERON-1","Inclusion Criteria:\n\n* The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent\n* Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent.\n* Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022).\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding or plans to become pregnant during the study.\n* Unstable medical condition or unstable chronic disease.\n* Significant neurological abnormality.\n* History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening.\n* History of seizure.\n* In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.","ALL","18 Years","75 Years",{"count":21,"type":22},118,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.",[28],"Major Depressive Disorder (MDD)",[30,31,32,33,34,35],"MDD","Depression","DT-101","Randomized","Placebo Controlled","Major Depressive Disorder","RECRUITING","2026-08-11",{"date":39,"type":40},"2026-08-12","ACTUAL",{"date":42,"type":40},"2026-05-14",{"date":44,"type":22},"2027-05",{"name":46,"class":47},"Draig Therapeutics Ltd","INDUSTRY",22,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100616081","phase-2-a-study-to-evaluate-the-effectiveness-of-dt-101-in-patients-with-depression-100616081","NCT07300969","A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression","A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder (MDD)","Tarian-1",{"count":57,"type":22},300,[25],"The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.",[28],[30,31,32,62,63,64],"randomized","placebo controlled","major depressive disorder","2026-07-02",{"date":67,"type":40},"2026-07-06",{"date":69,"type":40},"2025-12-16",{"date":71,"type":22},"2027-08",{"name":46,"class":47},40,""]